

United States Human Papillomavirus Vaccine Market Assessment, By Type [Tetravalent, Nonavalent, Bivalent, Quadrivalent], By Disease Indication [Cervical cancer, Anal cancer, Vulvar & Vaginal Cancer, Penile Cancer, Oropharyngeal Cancer, Others], By Category [Prophylactic vaccine, Therapeutic vaccine], By Method of synthesis [Nucleic acid-based, Peptide-based, Protein-based, Cell-based, Live-vector vaccine], By Recipient [Male, Female, Gender-neutral], By End-user [Hospitals, Specialty clinics, Homecare, Others], By Distribution Channel [Hospital, Retail Pharmacy, Online Pharmacy, Government, Non-Governmental Organisations], By Region, By Opportunities and Forecast, 2016-2030F

Market Report | 2024-04-19 | 119 pages | Market Xcel - Markets and Data

AVAILABLE LICENSES:

- Single User License \$3300.00
- Muti-User/Corporate Licence \$4500.00
- Custom Research License \$7000.00

Report description:

United States Human Papillomavirus Vaccine Market was valued at USD 2.76 billion in 2022, expected to reach USD 4.05 billion in 2030 with a CAGR of 4.9% for the forecast period between 2023 and 2030F. Several factors influence the human papillomavirus (HPV) vaccine market in the United States and have encompassed a heightened awareness of the importance of HPV vaccination. The escalating incidence of cervical cancer and other ailments associated with HPV, diverse governmental initiatives and vaccination campaigns, technological strides in vaccine creation, an amplified emphasis on cancer prevention, and an upswing in healthcare expenditures have collectively contributed to the overall expansion of the United States human papillomavirus vaccine

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

market.

Positioned at the forefront of healthcare advancements, the U.S. has proactively acknowledged the importance of HPV vaccination. The increasing recognition of the vaccine's role in preventing cervical cancer and related conditions has stimulated demand. Vaccination initiatives have been launched by strong governmental backing to achieve broader coverage. Progress in vaccine development technology has yielded the creation of HPV vaccines that are both highly effective and safe.

Amid a growing emphasis on cancer prevention, HPV vaccination has emerged as a pivotal strategy, further supported by the escalation of healthcare expenditures leading to growth in the United States human papillomavirus vaccine market. Consequently, the U.S. HPV vaccine market is experiencing an upward trajectory, driven by a holistic approach encompassing heightened awareness, government-driven efforts, technological advancements, and a pressing need for disease prevention.

High Prevalence of HPV Associated Diseases

High prevalence of HPV associated diseases is highly responsible for the growth of the United States human papillomavirus vaccine market. Human Papillomavirus stands as the prevalent sexually transmitted infection. In 2018, there were approximately 42.5 million individuals in the United States who contracted at least one HPV type capable of causing HPV-associated precancers, cancers, or anogenital warts. Moreover, around 13 million individuals acquired a new infection during that year. The overall prevalence of any HPV infection was 40.0%, with rates of 41.8% in males and 38.4% in females. Regarding disease-associated HPV infection, the prevalence was 24.2% in males and 19.9% in females. It is estimated that approximately 23.4 million males and females each had an infection with a disease-associated HPV type in 2018. The incidences of any HPV infection and disease-associated HPV infection were 1222 and 672 per 10,000 individuals, respectively. The incidence of disease-associated HPV infection was 708 per 10,000 in males and 636 per 10,000 in females. It is estimated that about 6.9 million males and 6.1 million females had an incident infection with a disease-associated HPV type in 2018.

Marked Awareness of HPV and the HPV Vaccine

In a recently published study on Scienedirect, researchers analyzed five HINTS data cycles to investigate shifts in the awareness of HPV and the HPV vaccine among American adults from 2008 to 2018. The study's findings highlighted that, compared to other nations, the awareness levels concerning HPV and the HPV vaccine are notably higher in the United States. However, despite an initial rise in awareness from 65% to 67% between 2008 and 2013, both HPV and HPV vaccine awareness exhibited a decline after 2013. By 2018, around 60% of US adults acknowledged being acquainted with both HPV and the HPV vaccine. Particularly noteworthy drops in awareness post-2013 were evident among males, individuals with limited educational attainment, and those with lower incomes. The study also delved into disparities in HPV and HPV vaccine awareness across periods, revealing that consistent lower awareness prevailed among demographic subsets such as racial/ethnic minority populations, rural residents, males, individuals aged 65 years and older, those with household incomes below \$35,000, and those with a high school education or lower. Marked awareness regarding HPV vaccine has significantly led to increased growth in the United States human papillomavirus vaccine market.

Government Initiatives

The government has embarked on substantial endeavors to encourage and improve nationwide human papillomavirus (HPV) vaccination, which has ultimately led to growth in the United States human papillomavirus vaccine market. These actions signify a forward-looking strategy to protect public health and diminish the occurrence of diseases linked to HPV. Through an emphasis on education, availability, and cost-effectiveness, these initiatives aspire to heighten HPV vaccination percentages, thereby positively impacting the general health and welfare of the populace. The Centers for Disease Control and Prevention (CDC) manage the Vaccines for Children (VFC) initiative, which supplies free of charge vaccines, including HPV, to healthcare providers for the immunization of adolescents. This program is accessible to all children below 18 years of age who are either covered by Medicaid or lack insurance. Healthcare providers also receive an administration fee from the Centers for Medicare and Medicaid Services (CMS) for delivering the vaccines.

Increasing Demand for HPV Vaccine for Head and Neck Cancer

The rising demand for the HPV vaccine to combat head and neck cancer underscores a critical shift in the United States human papillomavirus vaccine market. Healthcare systems and individuals alike recognize vaccination's potential as a proactive measure to mitigate the risks associated with these diseases. This essay delves into the factors driving the escalating demand for the HPV vaccine in the context of head and neck cancer, exploring the implications for public health and the broader healthcare landscape.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

For instance, in June 2020, Merck & Co., Inc., an American multinational pharmaceutical company, announced the approval by the U.S. Food and Drug Administration (FDA) for an extended usage of GARDASIL9. This extension pertains to preventing oropharyngeal and various head and neck cancers attributed to HPV Types 16, 18, 31, 33, 45, 52, and 58.

Quadrivalent Vaccines are Widely Used

The burgeoning demand for the quadrivalent vaccine has spurred growth within the United States human papillomavirus vaccine market. This quadrivalent HPV vaccine is formulated by combining four distinct HPV type-specific Virus-Like Particles (VLPs) sourced from HPV 6, 11, 16, and 18 L1 proteins, augmented with an aluminum adjuvant. Rigorous clinical trials have underscored the vaccine's exceptional effectiveness in preventing persistent HPV infections, as well as precursor lesions for cervical cancer, vaginal and vulvar cancers, and genital warts linked to HPV types 6, 11, 16, or 18 in females without prior infections from these HPV types. For example, in November 2022, Merck disclosed that an updated comprehensive analysis of worldwide data on the impact and efficacy of HPV vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] had been released online via the Expert Review of Vaccines journal. This meticulous review noted that the utilization of GARDASIL resulted in decreased occurrences of high-grade (precancerous) and low-grade cervical abnormalities, alongside reductions in specific non-cervical HPV-associated conditions and HPV infection rates among both women and men.

Impact of COVID-19

The COVID-19 pandemic has notably impacted the United States human papillomavirus vaccine market. According to a model-based analysis published by the National Centre for Biotechnology Information, the model population comprised individuals of all ages, both females and males, within the United States. The model contrasted pre-COVID vaccine utilization with three scenarios of diminished coverage, each with varying recovery rates. Vaccine coverage data were extracted from Truven Marketscan. Notably, reduced coverage from March to August 2020 was observed compared to 2018-2019 figures. The model's projections indicate that, in comparison to the status quo, an estimated 130,853 to 213,926 additional cases of genital warts, 22,503 to 48,157 cases of CIN1, 48,682 to 110,192 cases of CIN2/3, and 2,882 to 6,487 cases of cervical cancer may occur over the next century.

Key Players Landscape and Outlook

The landscape of the United States human papillomavirus vaccine market is marked by its dynamic nature, influenced by the interplay of pharmaceutical innovation, public health campaigns, and evolving consumer awareness. With the prominence of HPV-related diseases gaining attention due to their potential severity, the market's primary factors have assumed a central role in a crucial healthcare mission. This essay explores the present scenario and the prospective outlook of the HPV vaccine market in the US. It delves into the significant stakeholders, their contributions, the dynamics of competition, and the projected trends that will shape the market's trajectory in the foreseeable future. By scrutinizing the strategies, collaborations, and advancements embraced by these key participants, we glean insights into how the HPV vaccine market is poised to adapt to scientific progress and the changing demands of public health.

Table of Contents:

1. Research Methodology
2. Project Scope & Definitions
3. Impact of COVID-19 on United States Human Papillomavirus Vaccine Market
4. Executive Summary
5. United States Human Papillomavirus Vaccine Market Outlook, 2016-2030F
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.1.2. By Volume
 - 5.2. By Type
 - 5.2.1. Tetravalent
 - 5.2.2. Nonavalent
 - 5.2.3. Bivalent

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.4. □ Quadrivalent
- 5.3. □ By Disease indication
 - 5.3.1. □ Cervical cancer
 - 5.3.2. □ Anal cancer
 - 5.3.3. □ Vulvar & Vaginal cancer
 - 5.3.4. □ Penile cancer
 - 5.3.5. □ Oropharyngeal cancer
 - 5.3.6. □ Others
- 5.4. □ By Category
 - 5.4.1. □ Prophylactic vaccine
 - 5.4.2. □ Therapeutic Vaccine
- 5.5. □ By Method of synthesis
 - 5.5.1. □ Nucleic acid-based
 - 5.5.1.1. □ DNA
 - 5.5.1.2. □ mRNA
 - 5.5.2. □ Peptide-based
 - 5.5.3. □ Protein-based
 - 5.5.4. □ Cell-based
 - 5.5.5. □ Live vector vaccine
- 5.6. □ By Recipient
 - 5.6.1. □ Male
 - 5.6.2. □ Female
 - 5.6.3. □ Gender-neutral
- 5.7. □ By End-User
 - 5.7.1. □ Hospitals
 - 5.7.2. □ Specialty clinics
 - 5.7.3. □ Homecare
 - 5.7.4. □ Others
- 5.8. □ By Distribution Channel
 - 5.8.1. □ Hospital
 - 5.8.2. □ Retail Pharmacy
 - 5.8.3. □ Online Pharmacy
 - 5.8.4. □ Non-Governmental Organisations
- 5.9. □ By Region
 - 5.9.1. □ North
 - 5.9.2. □ South
 - 5.9.3. □ East
 - 5.9.4. □ West and Central
- 5.10. □ By Company Market Share (%), 2022
- 6. □ Market Mapping, 2022
 - 6.1. □ By Type
 - 6.2. □ By Disease indication
 - 6.3. □ By Category
 - 6.4. □ By Method of synthesis
 - 6.5. □ By Recipient
 - 6.6. □ By End-user
 - 6.7. □ By Distribution channel

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.8. By Region
- 7. Macro Environment and Industry Structure
 - 7.1. Supply Demand Analysis
 - 7.2. Import Export Analysis
 - 7.3. Value Chain Analysis
 - 7.4. PESTEL Analysis
 - 7.4.1. Political Factors
 - 7.4.2. Economic System
 - 7.4.3. Social Implications
 - 7.4.4. Technological Advancements
 - 7.4.5. Environmental Impacts
 - 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
 - 7.5. Porter's Five Forces Analysis
 - 7.5.1. Supplier Power
 - 7.5.2. Buyer Power
 - 7.5.3. Substitution Threat
 - 7.5.4. Threat from New Entrant
 - 7.5.5. Competitive Rivalry
- 8. Market Dynamics
 - 8.1. Growth Drivers
 - 8.2. Growth Inhibitors (Challenges and Restraints)
- 9. Regulatory Framework and Innovation
 - 10.1. Clinical Trials
 - 10.2. Patent Landscape
 - 10.3. Regulatory Approvals
 - 10.4. Innovations/Emerging Technologies
- 10. Key Players Landscape
 - 10.1. Competition Matrix of Top Five Market Leaders
 - 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
 - 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
 - 10.4. SWOT Analysis (For Five Market Players)
 - 10.5. Patent Analysis (If Applicable)
- 11. Pricing Analysis
- 12. Case Studies
- 13. Key Players Outlook
 - 13.1. GlaxoSmithKline PLC.
 - 13.1.1. Company Details
 - 13.1.2. Key Management Personnel
 - 13.1.3. Products & Services
 - 13.1.4. Financials (As reported)
 - 13.1.5. Key Market Focus & Geographical Presence
 - 13.1.6. Recent Developments
 - 13.2. Merck & Co., Inc.
 - 13.3. Beijing Health Guard Biotechnology, Inc.
 - 13.4. China National Biotec Group Company Limited
 - 13.5. Shanghai Bovax Biotechnology Co., Ltd.
 - 13.6. Walvax Biotechnology Co., Ltd

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.7. □Xiamen Innovax Biotech Co., Ltd.
- 13.8. □Serum Institute of India Pvt. Ltd.
- 13.9. □BioLeaders Corp.
- 13.10. □Eyegene Inc.
- 13.11. □2A Pharma AB
- 13.12. □Janssen Biotech, Inc.

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

- 14. □Strategic Recommendations
- 15. □About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

United States Human Papillomavirus Vaccine Market Assessment, By Type [Tetravalent, Nonavalent, Bivalent, Quadrivalent], By Disease Indication [Cervical cancer, Anal cancer, Vulvar & Vaginal Cancer, Penile Cancer, Oropharyngeal Cancer, Others], By Category [Prophylactic vaccine, Therapeutic vaccine], By Method of synthesis [Nucleic acid-based, Peptide-based, Protein-based, Cell-based, Live-vector vaccine], By Recipient [Male, Female, Gender-neutral], By End-user [Hospitals, Specialty clinics, Homecare, Others], By Distribution Channel [Hospital, Retail Pharmacy, Online Pharmacy, Government, Non-Governmental Organisations], By Region, By Opportunities and Forecast, 2016-2030F

Market Report | 2024-04-19 | 119 pages | Market Xcel - Markets and Data

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3300.00
	Muti-User/Corporate Licence	\$4500.00
	Custom Research License	\$7000.00
		VAT
		Total

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

□** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-16"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com